Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CETP | P11597 | 7/20 | 0.49 |
| ▸ | MME | P08473 | 7/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18602061 | 0.89 | CYP2C19 (0.44) | CYP2C19CETPMME | |
| SCHEMBL16908421 | 0.86 | CYP2C19 (0.42) | CYP2C19CETPMMEALDH1A1TSHR | |
| SCHEMBL1045249 | 0.86 | CETP (0.43) | CYP2C19CETPMME | |
| SCHEMBL810162 | 0.84 | CETP (0.49) | CYP2C19CETPMME | |
| SCHEMBL781736 | 0.82 | CETP (0.48) | CYP2C19CETPMMEALDH1A1SMN1; SMN2 | |
| SCHEMBL1534074 | 0.82 | CETP (0.48) | CYP2C19CETPMME | |
| SCHEMBL9971636 | 0.82 | CETP (0.48) | CYP2C19CETPMME | |
| SCHEMBL9974581 | 0.82 | CETP (0.48) | CYP2C19CETPMME | |
| SCHEMBL2203045 | 0.81 | CETP (0.47) | CYP2C19CETPMME | |
| SCHEMBL9972631 | 0.79 | CETP (0.47) | CYP2C19CETPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297081-B1 | 1-(2-ETHYL-BUTYL)-CYCLOHEXANECARBOXYLIC ACID ESTER AS AN INTERMEDIATE IN THE PREPARATION OF PHARMACEUTICALLY ACTIVE AMIDES | HOFFMANN LA ROCHE (CH) | 2017-03-08 | — | — | EP | claimed |
| CN-102066311-B | 1-(2-ethyl-butyl) -cyclohexanecarboxylic acid ester as an intermediate in the preparation of pharmaceutically active amides | HOFFMANN LA ROCHE | 2014-07-02 | — | — | CN | claimed |
| EP-2094636-B1 | PROCESS FOR PREPARING 1-(2-ETHYL-BUTYL)-CYCLOHEXANECARBOXYLIC ACID | HOFFMANN LA ROCHE (CH) | 2012-10-24 | — | — | EP | claimed |
| US-8071803-B2 | Process | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | claimed |
| JP-2011524399-A | — | — | 2011-09-01 | — | — | JP | claimed |
| CN-102066311-A | 1-(2-ethyl-butyl) -cyclohexanecarboxylic acid ester as an intermediate in the preparation of pharmaceutically active amides | HOFFMANN LA ROCHE | 2011-05-18 | — | — | CN | claimed |
| EP-2297081-A1 | 1-(2-ETHYL-BUTYL) -CYCLOHEXANECARBOXYLIC ACID ESTER AS AN INTERMEDIATE IN THE PREPARATION OF PHARMACEUTICALLY ACTIVE AMIDES | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | claimed |
| US-7863474-B2 | Process for the preparation of CETP(1) | HOFFMANN-LA ROCHE INC. (US) | 2011-01-04 | — | — | US | claimed |
| WO-2009153181-A1 | 1-(2-ETHYL-BUTYL) -CYCLOHEXANECARBOXYLIC ACID ESTER AS AN INTERMEDIATE IN THE PREPARATION OF PHARMACEUTICALLY ACTIVE AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | claimed |
| US-20090312569-A1 | NOVEL PROCESS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | claimed |
| US-20090240080-A1 | PROCESS FOR THE PREPARATION OF CETP(1) | HOFFMANN URSULA | 2009-09-24 | — | — | US | claimed |
| EP-2094636-A1 | PROCESS FOR PREPARING 1-(2-ETHYL-BUTYL)-CYCLOHEXANECARBOXYLIC ACID | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | claimed |
| US-20080154059-A1 | PROCESS FOR THE PREPARATION OF CETP(1) | HOFFMANN-LA ROCHE INC. | 2008-06-26 | — | — | US | claimed |
| WO-2008074677-A1 | PROCESS FOR PREPARING 1- (2-ETHYL-BUTYL) -CYCLOHEXANECARBOXYLIC ACID | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | claimed |
| EP-1935867-A1 | Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | claimed |
| CN-111073974-B | Genetic markers for predicting responsiveness to treatment | 豪夫迈·罗氏有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230151424-A1 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT | HOFFMANN-LA ROCHE INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | JAPAN TOBACCO, INC., A JAPAN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6426365-B1 | Anticholesterol agents; Cholesterol ester transfer protein (CETP); including dalcetrapib, S-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino) phenyl) 2-methylpropanethioate | JAPAN TOBACCO INC. (JP) | 2002-07-30 | — | — | US | disclosed |
| EP-1020439-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080154059-A1 | PROCESS FOR THE PREPARATION OF CETP(1) | CETP, CES1, CPA1 | CYP2C19 900/4885CETP 1/4885MME 417/4885 |
| US-20030092708-A1 | Anticholesterol agents; cardiovascular disorders; antilipemic agents | CETP, CES1, PON1 | CYP2C19 1065/4885CETP 1/4885MME 466/4885 |
| US-20090240080-A1 | PROCESS FOR THE PREPARATION OF CETP(1) | CETP, CES1, CPA1 | CYP2C19 900/4885CETP 1/4885MME 417/4885 |
| US-20230151424-A1 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT | CETP, HDLBP, APOB | CYP2C19 1830/4885CETP 1/4885MME 581/4885 |
| US-20090312569-A1 | NOVEL PROCESS | CYP3A5, MCCC2, CYP3A4 | CYP2C19 35/4885CETP 683/4885MME 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.